Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

754
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
754
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

42
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
42
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

69
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
69
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

88
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
88

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ceftriaxone-resistant multidrug-resistant <i>Salmonella</i> Typhi sepsis in pregnancy.

BMJ case reports·2026
Same author

Factors Influencing Lesion Titration in a Monopolar Pulsed-Field Ablation Point Catheter: A Preclinical Study.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Assessing the cardiovascular and potassium lowering effects of levalbuterol compared to albuterol: a randomized control trial.

Frontiers in cardiovascular medicine·2025
Same author

Intracardiac echocardiography guided anatomical approach to cardioneuroablation: feasibility and outcomes.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

Age-stratified outcomes of transvenous lead extraction: A 5090-patient experience from the ExTRACT registry.

Heart rhythm·2025
Same author

Outcomes of stylet-driven leads compared to lumenless leads for left bundle branch are pacing: systematic review and meta-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Sep 22, 2025

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.4K

Coenzyme Q10 for heart failure.

Tareq Al Saadi1, Yazan Assaf2,3, Medhat Farwati2,4

  • 1Department of Internal Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, Illinois, USA.

The Cochrane Database of Systematic Reviews
|May 24, 2022
PubMed
Summary
This summary is machine-generated.

Coenzyme Q10 (CoQ10) supplementation likely reduces mortality and hospitalizations in heart failure patients. However, evidence for its effects on myocardial infarction, stroke, and exercise capacity is inconclusive, warranting further research.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.0K
Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

2.0K

Related Experiment Videos

Last Updated: Sep 22, 2025

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.4K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.0K
Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

2.0K

Area of Science:

  • Cardiology and Cardiovascular Diseases
  • Nutritional Biochemistry and Metabolism
  • Mitochondrial Function and Oxidative Stress

Background:

  • Coenzyme Q10 (ubiquinone) is a vital mitochondrial electron carrier and coenzyme.
  • CoQ10 deficiency is linked to heart failure severity and increased oxidative stress.
  • Potential roles in myocardial ion channel stabilization and ATP synthesis support its investigation in heart failure.

Purpose of the Study:

  • To systematically review the safety and efficacy of coenzyme Q10 (CoQ10) in managing heart failure.
  • To synthesize evidence from randomized controlled trials (RCTs) comparing CoQ10 with placebo or conventional therapy.

Main Methods:

  • Comprehensive search of multiple databases (CENTRAL, MEDLINE, Embase, etc.) up to October 2020.
  • Inclusion of 11 RCTs (parallel or cross-over) involving 1573 participants with heart failure.
  • Risk of bias assessment using Cochrane tools and evidence quality evaluation via GRADE methods; meta-analysis where feasible.

Main Results:

  • Moderate-quality evidence suggests CoQ10 probably reduces all-cause mortality (RR 0.58) and heart failure hospitalizations (RR 0.62).
  • Low-quality evidence shows inconclusive effects on myocardial infarction and stroke risk.
  • Very low-quality evidence indicates uncertainty regarding CoQ10's impact on left ventricular ejection fraction and exercise capacity; adverse event risk appears similar to placebo.

Conclusions:

  • Coenzyme Q10 demonstrates probable benefits in reducing mortality and hospitalizations for heart failure, supported by moderate-quality evidence.
  • Current evidence is insufficient to confirm or refute CoQ10's efficacy for myocardial infarction, stroke, or exercise parameters.
  • Further high-quality trials are necessary to definitively establish the role of CoQ10 in heart failure management.